Loading…
Loading…
EVFM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EVFM and 80,000+ other tickers.
See exactly how EVFM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EVFM and 80,000+ other tickers.
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
TEL AVIV, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), today announced that it has acquired certain senior subordinated convertible notes and purchase rights of Evofem Biosciences, Inc. (OTCMKTS: EVFM) (“Evofem”), funded entirely with HUB equity at no cash cost to the Company.
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as.
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory). SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial vag.
Valuation and Earnings This table compares Ayala Pharmaceuticals and Evofem Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24 million 11.05 -$48.07 million ($5.02) -0.12 Evofem Biosciences $11.39 million 0.10 $52.98 million ($0.03) -0.28 Evofem Biosciences has higher revenue and earnings
SAN DIEGO--(BUSINESS WIRE)---- $EVFM #BV--Women's health pioneer Evofem reported its fifth consecutive year of top line growth, with 2025 net product sales of more than $20 million.